Company intelligence / Profile preview

Stormotion

Cambridge, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

STORM’s lead candidate, STC‑15, is the first-in-class inhibitor of the RNA methyltransferase METTL3 and represents the first ever RNA modifying enzyme inhibitor to enter clinical evaluation in humans. A Phase 1 trial in cancer patients began in November 2022. Additional programs are advancing toward IND-enabling studies targeting oncology, inflammation, CNS, and viral diseases.

Therapeutic areas: OncologyImmunologyNeurologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Stormotion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stormotion.

Explore the full profile